SCHEMBL3860243

SCHEMBL3860243

COc1ccc(NC(=O)c2cc(O)cc(O)c2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 13/20 0.72
RAB9A P51151 12/20 0.72
SMN1; SMN2 Q16637 6/20 0.72
TP53 P04637 5/20 0.72
ALOX15 P16050 1/20 0.72
NQO2 P16083 1/20 0.69
CASP3 P42574 4/20 0.66
SENP7 Q9BQF6 4/20 0.66
TAS1R3 Q7RTX0 1/20 0.66
TAS1R1 Q7RTX1 1/20 0.66
TAS1R2 Q8TE23 1/20 0.66
ALOX5 P09917 1/20 0.62
ALDH1A1 P00352 4/20 0.61
KMT2A Q03164 4/20 0.61
MEN1 O00255 3/20 0.61
CYP1A2 P05177 2/20 0.61
CYP3A4 P08684 1/20 0.61
GAA P10253 1/20 0.61
CYP2D6 P10635 1/20 0.61
CYP2C9 P11712 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917029 0.90 NPC1 (0.82) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL28937078 0.85 TOP1 (0.74) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL8398096 0.85 RAB9A (0.86) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL5399964 0.85 RAB9A (0.86) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL3869333 0.85 KMT2A (0.68) NPC1RAB9ASMN1; SMN2TP53NQO2
SCHEMBL18063675 0.85 NPC1 (0.63) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL6799157 0.84 RAB9A (1.00) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL16675165 0.83 NPC1 (0.83) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL16675159 0.83 NPC1 (0.83) NPC1RAB9ASMN1; SMN2TP53ALOX15
SCHEMBL715515 0.82 NQO2 (1.00) NPC1RAB9ATP53NQO2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1915337-A4 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORP (KR) 2009-04-22 EP disclosed
US-20080280989-A1 Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same AMOREPACIFIC CORPORATION (KR) 2008-11-13 US disclosed
EP-1915337-A1 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME Amorepacific Corporation (KR) 2008-04-30 EP disclosed
WO-2007021067-A1 HYDROXYBENZAMIDE DERIVATIVES, THE METHOD FOR PREPARING THEREOF AND THE COSMETIC COMPOSITION CONTAINING THE SAME AMOREPACIFIC CORPORATION (KR) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280989-A1 Hydroxybenzamide Derivatives, the Method For Preparing Thereof and the Cosmetic Composition Containing the Same H1-0, HAAO, H1-10 NPC1 4272/4885RAB9A 2523/4885SMN1; SMN2 2739/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.